A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
The reason for this study is to compare the efficacy of abemaciclib, in combination with
 fulvestrant, to that of physician's choice of chemotherapy in women with hormone
 receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic
 breast cancer that has spread to internal organs. Your participation in this trial could last
 up to 31 months, depending on your cancer type and how you and your tumor respond.
Inclusion Criteria:

 -  Participants must be females of post-menopausal status with HR+, HER2- breast cancer
 that has spread to internal organs

 -  Participants must have had at least one endocrine therapy

 -  Participants must be willing to use a device to answer daily questions about how they
 are doing for the duration of their participation in the study

 -  If participant has diarrhea from a previous treatment, they should talk to their
 doctor to ensure they have recovered enough to participate in this study

 Exclusion Criteria:

 -  Participants must not have breast cancer that has spread to the brain if untreated and
 with symptoms

 -  Participants must not have had any systemic treatment after their breast cancer has
 spread unless it is endocrine therapy

 -  Participants must not have certain active infections including HIV or hepatitis

 -  Participants must not be pregnant or breastfeeding

 -  Participants must not have certain types of cancers or certain previous cancer
 treatments

 -  Participants must not have certain serious medical conditions, including heart or lung
 disease, or have had certain types of tissue or organ transplants